News and Events
ArtVentive Successfully Completes FDA Audit
As part of transition to a new line of production and preparing it for commercial release in the US, followed by EU and rest of the World, ArtVentive has successfully passed its FDA audit which opens a new stage of production and marketing of the EOS plugs.
February 2024
2023: ArtVentive EOS-X Transfer into Full Scale Production.
Preparing the new product line to commercialization and revenue phase.
Following FDA approval of ArtVentive's new product line - EOS plugs featuring extended range of treatable vessels and reduced delivery profile, the Company initiated transfer into full scale production.
ArtVentive Medical Group, Inc's EOS Obtains Approval in Japan
March 10, 2022
ArtVentive Medical Group Announces FDA Clearance of EOS-X Endoluminal Occlusion System
March 7, 2022
For full press release: https://www.accesswire.com/viewarticle.aspx?id=691755
Bill Olson Appointed CEO of ArtVentive Medical Group, Inc.
January 3, 2022
For full press release: https://www.einnews.com/pr_news/559710356/artventive-medical-group-announces-appointment-of-bill-olson-as-ceo
ArtVentive and SIR conference
The SIR 2020 conference to be held in Seattle, WA, USA, from March 28 to April 2, is cancelled.
ArtVentive Medical Group Inc. will welcome you at the next SIR conference.
ArtVentive at PAIRS 2020 in Dubai
Dec 16, 2019 | Press Release
ArtVentive Medical Group Inc will be present at the PAIRS conference held in Dubai, from February 26 to 29, 2020. You are invited to come and experience the unique features of the EOS Plug at booth #3.
ArtVentive at GEST 2019
Apr 8, 2019 | Press Release
Visit us at GEST 2019, Booth # 111 ArtVentive Medical will participate in the 13th Annual GEST Meeting to be held from May 9 -12, In the Sheraton New York Times Square Hotel, New York City, NY. ArtVentive will feature an exhibit booth, hands on product demonstration...
ArtVentive at SIR-2019
Jan 15, 2019 | Events, News, Press Release
Visit us at SIR-2019, Booth # 705 ArtVentive Medical will participate in the Annual Scientific Meeting of the US Society of Interventional Radiology (SIR-2019). The meeting will be held on March 24-27 in Austin, TX. ArtVentive will feature an exhibit booth, hands on...
In Vitro study on EOS Plug for Percutaneous Transrenal Ureter Occlusion
Oct 23, 2018 | Press Release
At CIRSE 2018 in Lisbon, Dr. Daniel Kuetting of the Radiology Department of the University Hospital in Bonn, Germany, presented the successful results of their in-vitro study on the Occlusive Properties of the ArtVentive EOS Plug for Percutaneous Transrenal Ureter...
Extended CE Mark certification for the EOS Plug
Oct 11, 2018 | Press Release
ArtVentive obtained the CE Mark extension for its flagship product: EOS™ vascular Plug. The extension of the European Certificate is enabling ArtVentive commercial activities in the EU for the next 5 years. The ArtVentive Endoluminal Occlusion System, EOS™ Plug is...
ISO-2016 certification for ArtVentive Medical Group Inc.
Oct 11, 2018 | Press Release
ArtVentive Medical Group Inc. is proud to announce that it has passed the audit and obtained the ISO-2016 certification with the highest possible score: 100 out of 100. No Nonconformities.
Overview EOS publications and abstracts at SIR 2018 and GEST 2018 US
Jun 6, 2018 | Publications
Overview EOS™ publications: Publications GEST-2018-Cionfoli GEST-2018-The GEST-2018-Deib-JHUxs SIR 2018-Kütting SIR-2018-Ferra-Varicocele a...
EOS Plug demonstrated in Hands-on workshops at SIR 2018 and GEST 2018 US
Jun 6, 2018 | Press Release
Both at SIR 2018 and at GEST 2018 US, the use of EOS™ Plug was demonstrated in Hands-On workshops. Physicians learned all about EOS’s simple plug deployment and precise placement, leading to immediate and permanent vessel occlusion.
EOS Plug featured in abstracts/posters at GEST, Miami Beach, May 17-20
Apr 27, 2018 | Press Release
ArtVentive’s EOS™ Plug presented in multiple abstracts/posters at the GEST 2018 US conference, in Miami Beach, from May 17 – 20. Physicians from Germany, Italy, the Netherlands and the US will present their clinical experience with the EOS Plug. Also, there...
ArtVentive at the SIR meeting, Los Angeles, March 17-22, 2018
Jan 30, 2018 | Press Release
Visit us at booth #845 to learn more about the EOS™ Plug and its unique ability to immediately occlude blood flow in veins and arteries: www.sirmeeting.org. On Tuesday, March 20th from 3-4:30 pm, a hands-on Coils, Plugs & Embolics workshop is...
News Release: Corporate Update – APRIL 2017
May 3, 2017 | Press Release
We started commercial sales activity of the ArtVentive EOS™ in April 2016. From the very beginning, ArtVentive adopted a focused approach to the sales process, development and continuous growth. In the European markets, we market and sell our products through industry distributors. In the U.S, we market directly to selected University Hospitals and private clinics constantly expanding the customer base. We have targeted sales and marketing efforts to interventional radiologists and vascular surgeons with experience using similar catheter-based procedures, such as angioplasty and stenting. Peer-to-peer education is also a key element of our sales strategy.
Our progress to date has been significant where we have achieved 400 – 500% sales growth per quarter. Management is very confident in sales development and our company’s expansion based on natural organic growth.
ArtVentive Medical Group, Inc. Files Form 15 with the Securities and Exchange Commission Focusing on Rapid Sales Growth Not Public Reporting
Mar 24, 2017 | News
ArtVentive Medical Group, Inc. (“ArtVentive”) announced today that it filed a Form 15 with the Securities and Exchange Commission relieving it of all reporting requirements with the Securities and Exchange Commission.
Visit ArtVentive at GEST Europe 2017 in Florence
Mar 21, 2017 | Events, News
ArtVentive will attend GEST Europe in Florence, Italy from May 31 to June 3 Visit us at booth #9 to learn more about the EOS™ Plug and let us demonstrate its unique ability to immediately occlude blood flow in veins, arteries and tubes in the human...
ArtVentive Concludes Successful Clinical Demonstrations of the Revolutionary EOS™ Occlusion System at SIR 2017 in Washington DC.
Mar 9, 2017 | News
The ArtVentive team conducted a series of very successful meetings and workshops at the conference with EOS™ which was featured in several prominent events held at the conference auditorium, the exhibition floor and at hands-on workshops.
EOS™ attracted considerable attention from the audience, primarily interventional radiologists from the US, Europe, Australia and Asia, because it is the only occlusion device that immediately, safely and accurately stops blood flow.
ArtVentive EOS™ Device featured at SIR 2017 Conference in Washington, D.C.
Mar 6, 2017 | Press Release
ArtVentive EOS™ Device featured at SIR 2017 Conference
Visit us at booth #560.
Evaluation of Effectiveness of Embolization in Pelvic Congestion Syndrome with the New Vascular Occlusion Device (ArtVentive EOS™): Preliminary Results
Jun 13, 2016 | Publications
Successful embolization procedures with ArtVentive EOS™. This study aimed to collect confirmatory data in support of the safety and efficiency of the ArtVentive EOS™ for the treatment of pelvic congestion syndrome (PCS). A decrease in pelvic pain intensity based on the VAS was considered a clinical success.
ArtVentive Launches U.S. commercialization by Showcasing its EOS™ Device at GEST-2016. May 2016, New York
May 12, 2016 | Events, News, Press Release
ArtVentive Medical Group, Inc. commenced the launch of its flagship occlusion device product, the ArtVentive Endoluminal Occlusion System (EOS™) at the Global Embolization Symposium and Technologies (GEST) in New York, NY on May 5-8. The introduction in the United States follows the initial commercialization in the E.U. last year.
Visit ArtVentive at GEST 2016
Mar 15, 2016 | Events
Join us at the ArtVentive Booth #28 to learn more about the EOS™ Endoluminal Occlusion System at the GEST 2016 U.S. conference in New York.
Conference Dates: 05/05/16 – 05/08/16.
Adriaan Moelker, MD, PhD to Present ArtVentive EOS™ Device Poster at GEST 2016
Mar 15, 2016 | Press Release
Adrian Moelker, MD, PhD, a radiologist at the Erasmus MC-University Medical Centre in the Netherlands, will present his poster abstract on the ArtVentive EOS™ Device at the GEST 2016 U.S. conference in New York conference in May
Successful Occlusion of the Splenic Artery Using the Endoluminal Occlusion System
Oct 30, 2015 | Publications
The occlusion of blood vessels with the use of endovascular techniques is a fundamental concept for interventional management of urgent and emergent vascular conditions (1,2). However, complete and durable vessel occlusion is difficult to achieve with the currently available mechanical devices, most common among which are coils or plugs. The endoluminal occlusion system (EOS™; ArtVentive, Carlsbad, California) is a family of catheter-based, expandable endoluminal mechanical occlusion devices. The possible clinical indications of the EOS™ device include the management of venous (e.g., varicocele, ovarian varices, varicose veins) and arterial (e.g., emergency arterial embolization in trauma patients) conditions. As no late imaging was obtained in the present case, durable occlusion with the EOS™ device could be assessed in future studies.
To conclude, the EOS™ may provide a safe and reliable method of immediate vessel occlusion in the peripheral arterial circulation.
ArtVentive Medical Receives FDA Clearance for Larger Size EOS™ Device
Sep 29, 2015 | News, Press Release
ArtVentive Medical Group, Inc. (OTC Bulletin Board AVTD) announced today that it has received U.S. Food and Drug Administration (FDA) clearance for its 11mm Endoluminal Occlusion System (EOS™).
ArtVentive EOS™ Device Featured at GEST Conference in Seville Spain
Jul 8, 2015 | News, Press Release
ArtVentive Medical Group, Inc. announced today that the Company’s Endoluminal Occlusion System (EOS™(TM)) was featured in presentations at…
ArtVentive Medical Group, Inc. Featured in Scientific Session at the European Vascular Conference
Mar 11, 2015 | News, Press Release
ArtVentive Medical Group, Inc. announced today that the Company’s Endoluminal Occlusion System (EOS™(TM)) was featured in a presentation at the recent European Vascular Conference (EVC) in Maastricht, the Netherlands…
ArtVentive Medical Group, Inc. Announces First Use of ArtVentive EOS™ in the United States
Mar 3, 2015 | Press Release
March 03, 2015 08:05 AM Eastern Standard Time CARLSBAD, Calif. (BUSINESS WIRE) ArtVentive Medical Group, Inc. (OTC Bulletin Board: AVTD) announced today the first use of its Endoluminal Occlusion System (EOS™) in the United States at The Johns Hopkins...
With FDA Approval, ArtVentive Medical Expands into the U.S. Markets with the Addition of a Regional Sales Director
Jan 5, 2015 | News
CARLSBAD, CA / ACCESSWIRE / January 5, 2015 / ArtVentive Medical Group, Inc. (OTC Bulletin Board AVTD) announced the addition of Mr. Joe Harsa to its sales organization as Regional Sales Director for the Eastern Region of the U.S. “The Company’s launch of...
ArtVentive Medical Group, Inc. receives U.S. Food and Drug Administration (FDA) clearance for the Endoluminal Occlusion System (EOS™)
Dec 5, 2014 | News
December 04, 2014 03:33 PM Eastern Standard Time CARLSBAD, Calif. (BUSINESS WIRE) ArtVentive Medical Group, Inc. (OTC Bulletin Board AVTD) announced today that it has received U.S. Food and Drug Administration (FDA) clearance for the Endoluminal Occlusion...
ArtVentive Medical Group, Inc. Announces Expanded Commercial Use and Post-Market Study of EOS™ Endoluminal Occlusion System
Oct 17, 2014 | News
CARLSBAD, CA (Marketwired – Oct 14, 2014) ArtVentive Medical Group, Inc. (OTCBB: AVTD) announced today additional excellent clinical results in the ongoing ArtVentive EOS™ Endoluminal Occlusion System, or ArtVentive EOS™, OCCLUDE I post-market...
ArtVentive Medical Group, Inc. Announces Addition to European Sales Management Team
Sep 15, 2014 | News
Source: ArtVentive Medical Group, Inc. On Wednesday, September 10, 2014 at 10:23 AM ET CARLSBAD, CA (Marketwired – Sep 10, 2014) ArtVentive Medical Group, Inc. (OTCBB: AVTD) announced today the addition of Henk van der Laak to its sales management...
ArtVentive Medical Group, Inc. Announces Excellent Clinical Results and Expanded Enrollment in OCCLUDE I Post-Market Surveillance Study
Aug 1, 2014 | News
July 31, 2014 08:05 AM Eastern Daylight Time CARLSBAD, Calif. (BUSINESS WIRE) ArtVentive Medical Group, Inc. (OTC Bulletin Board: AVTD) announced today excellent clinical results in conjunction with expanded enrollment in the ArtVentive Endoluminal...
ArtVentive Medical Group, Inc. Announces Upcoming Conference and ArtVentive EOS™ Physician Training Programs
May 8, 2014 | News
May 5, 2014 12:03 UTC CARLSBAD, Calif. (BUSINESS WIRE) ArtVentive Medical Group, Inc. (OTCBB: AVTD) announced today that the Company will attend the 18th annual European Vascular Conference (“EVC”) in Maastricht, the Netherlands from May 12th to the 14th...
ArtVentive Medical Group, Inc. Announces the Expansion of its International Distributor Network
Apr 23, 2014 | News
CARLSBAD, Calif. (BUSINESS WIRE) ArtVentive Medical Group, Inc. (OTCBB: AVTD) announced today that it is executing the planned expansion of its European distributor network to provide product training and support to distributors in 15 countries. This...
A New Occlusion Device: Application of the ArtVentive Endoluminal Occlusion System (EOS™)—First in Human Clinical Trial
Mar 29, 2014 | Publications
Purpose: The purpose of this study was to determine the safety and efficacy of a new endoluminal occlusion device, ArtVentive endoluminal occlusion system (EOS™), to occlude the spermatic vein in symptomatic males with varicoceles.
Methods: The ArtVentive EOS™ device has been developed for percutaneous occlusion of the peripheral arterial and venous vasculature.
Results: The acute occlusion rate at the end of the procedure was 100 % occurring in nine of nine vessels. The spermatic veins of all patients remained occluded on venography at 30 days follow-up. Pain scores related to varicoceles decreased in five of six patients.
Conclusions: Although we recognize this study is limited, initial experience indicates that the ArtVentive EOS™ is a safe and effective new device for occlusion of vessels (varicoceles). The device has potential applications in other clinical conditions requiring occlusion of veins or arteries.
Industry Veteran Joins ArtVentive Medical Group, Inc. as SVP of Global Marketing and North American Sales
Jan 10, 2014 | News
CARLSBAD, Calif. (BUSINESS WIRE) ArtVentive Medical Group, Inc. (OTC Bulletin Board: AVTD) today announced the addition of Mr. John Rappe to the executive team as Senior Vice President of Global Marketing and North American Sales. “The Company’s momentum...
ArtVentive Medical Group, Inc. Announces the Receipt of the CE Mark Certification
Jun 3, 2013 | News
CARLSBAD, Calif. (BUSINESS WIRE) ArtVentive Medical Group, Inc. (OTC Bulletin Board: AVTD) announced today that the Company has received its European CE Mark certification for the ArtVentive EOS™ Peripheral Vascular Endoluminal Occlusion system. “This is...
First Human Study Proves 100% Occlusion of Vessels
Jun 27, 2011 | News
CARLSBAD, Calif. (BUSINESS WIRE) ArtVentive Medical Group, Inc. (OTCBB: AVTD) announced today that the Company has conducted its First Human Clinical Study with its EOS™ Peripheral vascular occlusion device. The study involved six male patients who had...
ArtVentive Medical Group, Inc., EOS™ Device Proves 100% Occlusion of Blood Vessels
May 9, 2011 | News
SAN MARCOS, Calif. (BUSINESS WIRE) ArtVentive Medical Group, Inc. (OTCBB: AVTD) announced today that the Company performed regulatory animal studies treating target vessels with its occlusion system – (EOS) device. The procedures had a 100% success rate...
ArtVentive Medical Group, Inc. Announces EOS™ Device Freeze
Mar 18, 2011 | News
SAN MARCOS, Calif. (BUSINESS WIRE) ArtVentive Medical Group, Inc. (OTC Bulletin Board: AVTD) announced today that the Company has frozen its Endoluminal Occlusion (EOS™) device design for the peripheral category of indications in preparation for the...
ArtVentive Medical Group, Inc. Secures $10,000,000 in Financing
Feb 4, 2011 | News
SAN MARCOS, Calif. (BUSINESS WIRE) ArtVentive Medical Group, Inc. (OTCBB: AVTD) announced today a ten million-dollar ($10,000,000 USD) financing agreement with a European financial group. A firm commitment for the first tranche of $1,950,000 is at $.90...
ArtVentive Medical Group, Inc. and Northwest Clinical Research Group, Inc. Sign Agreement
Sep 1, 2010 | News
SAN MARCOS, Calif.– (BUSINESS WIRE) — ArtVentive Medical Group, Inc. (OTC Bulletin Board: AVTD) announced today that the Company has entered into a strategic agreement with the internationally renowned regulatory, clinical and quality assurance group.
ArtVentive Medical Group, Inc. and Medical Murray Inc. Sign Agreement
Aug 23, 2010 | News
ArtVentive Medical Group, Inc. (OTC Bulletin Board: AVTD) announced the Company has signed a manufacturing research and development agreement with Medical Murray Inc. (ISO certified and FDA registered). Medical Murray is a leader in medical device and product development including specialty manufacturing services.
EOS™ Plug
Jan 2, 2010 | Press Release
The AVMG EOS™ device enables minimally-invasive blockage of targeted veins, arteries and tubes within the body.